Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 4/20 | 0.38 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10590259 | 0.85 | MAOA (0.48) | HTR6MAOACES1MAOBBCHE | |
| SCHEMBL7749803 | 0.81 | CES1 (0.43) | MAOACES1MAOBTDP1CYP2A6 | |
| SCHEMBL29648452 | 0.81 | CES1 (0.43) | MAOACES1MAOBTDP1CYP2A6 | |
| SCHEMBL27590862 | 0.80 | HTR6 (0.37) | HTR6MAOACES1MAOBBCHE | |
| SCHEMBL11728305 | 0.80 | HTR6 (0.37) | HTR6MAOACES1MAOBBCHE | |
| SCHEMBL7636832 | 0.80 | ADRA1D (0.37) | HTR6MAOACES1MAOBBCHE | |
| SCHEMBL14672853 | 0.77 | HTR6 (0.35) | HTR6MAOACES1 | |
| SCHEMBL14672854 | 0.77 | HTR6 (0.35) | HTR6MAOACES1 | |
| SCHEMBL19750905 | 0.77 | HTR6 (0.35) | HTR6MAOACES1 | |
| SCHEMBL276262 | 0.76 | MAOA (0.41) | HTR6MAOACES1MAOBBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0469887-B1 | Acetamide derivatives | ZENECA LTD (GB) | 1994-12-14 | — | — | EP | claimed |
| EP-0469887-A1 | Acetamide derivatives | ZENECA LIMITED (GB) | 1992-02-05 | — | — | EP | claimed |
| US-12030896-B2 | PIKfyve inhibitors | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-07-09 | — | — | US | disclosed |
| CN-110099951-B | Surface treated fillers for polyester films | OMYA国际股份公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-112105654-A | Curable resin mixture, curable resin composition, and cured product thereof | 日本化药株式会社 | 2020-12-18 | — | — | CN | disclosed |
| CN-109369523-A | A kind of Preparation method and use of tetrahydroisoquinoliderivs derivs | 安阳师范学院 | 2019-02-22 | — | — | CN | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-9993459-B2 | Selective HDAC6 inhibitors and uses thereof | UNIVERSITEIT GENT (BE) | 2018-06-12 | — | — | US | disclosed |
| US-20180093971-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2018-04-05 | — | — | US | disclosed |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170360748-A1 | SELECTIVE HDAC6 INHIBITORS AND USES THEREOF | UNIVERSITEIT GENT (BE) | 2017-12-21 | — | — | US | disclosed |
| US-4684735-A | Promotion of raney nickel hydrogenation catalyst | STAUFFER CHEMICAL COMPANY (US) | 1987-08-04 | — | — | US | disclosed |
| US-4650876-A | INCREMENTAL ADDITION TO PREVENT FOAMING, RANEY CATALYST | STAUFFER CHEMICAL COMPANY (US) | 1987-03-17 | — | — | US | disclosed |
| EP-0210683-A1 | Promotion of raney nickel catalyst | STAUFFER CHEMICAL COMPANY (US) | 1987-02-04 | — | — | EP | disclosed |
| US-4613691-A | Preparation of amino acids from unsaturated hydantoins | STAUFFER CHEMICAL COMPANY (US) | 1986-09-23 | — | — | US | disclosed |
| EP-0184550-A2 | 5-Amino-4-hydroxy valeryl amide derivatives | CIBA-GEIGY AG (CH) | 1986-06-11 | — | — | EP | disclosed |
| US-4582903-A | Synthesis of unsaturated hydantoins with an inexpensive catalyst | STAUFFER CHEMICAL COMPANY (US) | 1986-04-15 | — | — | US | disclosed |
| EP-0177072-A2 | Preparation of amino acids from unsaturated hydantoins | STAUFFER CHEMICAL COMPANY (US) | 1986-04-09 | — | — | EP | disclosed |
| US-4017313-A | Photosensitive composition containing a leuco dye, a photosensitizer, an aromatic aldehyde and a secondary or tertiary amine and the use thereof in a direct-print process | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-04-12 | — | — | US | disclosed |
| US-3987116-A | ETHYNYLARYL COMPOUNDS AND DERIVATIVES THEREOF | WILLIAM H. RORER, INC. (US) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030896-B2 | PIKfyve inhibitors | PIKFYVE, PIP4K2B, PIP4K2A | HTR6 4111/4885MAOA 4504/4885CES1 2547/4885 |
| US-20170360748-A1 | SELECTIVE HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | HTR6 2012/4885MAOA 1686/4885CES1 3254/4885 |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | BRDT, BRD4, BRD1 | HTR6 3369/4885MAOA 4049/4885CES1 1867/4885 |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | MCL1, ABL1, FLT3 | HTR6 4195/4885MAOA 3677/4885CES1 2646/4885 |
| US-20180093971-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | HTR6 4182/4885MAOA 953/4885CES1 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.